Two Welsh health boards will keep running Genedrive's MT-RNR1 hearing loss test as routine practice until NICE issues final guidance next year.

Mark Winkler and Mike Fairbourn will join the Genedrive board on 1 September as the company works to scale its pharmacogenetic testing business in the UK and internationally.

Genedrive has finished recruiting nearly 6,000 babies to its PALOH-UK trial, clearing a key evidence hurdle as the test moves into NICE's technology appraisal process.

Erasmus MC becomes the first Netherlands medical centre to roll out genedrive's rapid newborn hearing-loss test.

The new clinical edict says MT-RNR1 genotype testing before aminoglycoside treatment, naming Genedrive's point-of-care kit for use in acute care settings.

"As we continue to accelerate the adoption of our pharmacogenetic tests in the UK and internationally, Graham's strategic expertise and guidance will be integral to the Board," said Dr Gino Miele

"The last year has seen significant commercial and operational progress for genedrive", said chief executive Dr Gino Miele, pointing to expanding NHS adoption of both tests and strengthened activity across Europe and the Middle East.

A government minister named Genedrive's newborn hearing-loss test as a live example of personalised medicine during a House of Commons committee session.

Dr. Ian Gilham has left the Genedrive board as the point-of-care pharmacogenetic testing company searches for a new independent Non-Executive Chairman and two additional non-executive directors.

It will develop a laboratory-based pharmacogenetic test for deployment on Thermo Fisher Scientific's QuantStudio 5 Dx platform, targeting the UK NHS genomic laboratory market.

"The Genedrive assay has become an integral part of our neonatal practice, enabling rapid identification of babies at risk of aminoglycoside-induced hearing loss," said Dr Ajit Mahaveer

It has received an R&D tax credit refund of approximately £0.76m covering the financial years ended 30 June 2024 and 30 June 2025.

David Nugent will be Non‑Executive Director with immediate effect, with Dr Ian Gilham stepping down by the end of June.

genedrive plc’s point‑of‑care MT‑RNR1 test is now explicitly scoped in NHS England’s market engagement notice, which signals a planned tender publication on 1 January 2027 and a go‑live target of 1 July 2027.